Antiherpes Virus–Specific Treatment and Cognition in Schizophrenia: A Test-of-Concept Randomized Double-Blind Placebo-Controlled Trial | Zendy

Konasale M. Prasad | Zendy; Shaun M. Eack | Zendy; Matcheri S. Keshavan | Zendy; Robert H. Yolken | Zendy; Satish Iyengar | Zendy; Vishwajit L. Nimgaonkar | Zendy

Open Access

Antiherpes Virus–Specific Treatment and Cognition in Schizophrenia: A Test-of-Concept Randomized Double-Blind Placebo-Controlled Trial

Author(s) -

Konasale M. Prasad,

Shaun M. Eack,

Matcheri S. Keshavan,

Robert H. Yolken,

Satish Iyengar,

Vishwajit L. Nimgaonkar

Publication year - 2012

Publication title -

schizophrenia bulletin

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.823

H-Index - 190

eISSN - 1745-1707

pISSN - 0586-7614

DOI - 10.1093/schbul/sbs040

Subject(s) - placebo , neurocognitive , verbal learning , schizophrenia (object oriented programming) , psychopathology , psychology , cognition , randomized controlled trial , verbal memory , clinical psychology , working memory , psychiatry , medicine , alternative medicine , pathology

To test our hypothesis that valacyclovir, an antiherpes virus-specific medication, added to antipsychotics (APs) would improve cognitive performance and psychopathology among schizophrenia subjects exposed to neurotropic herpes simplex virus, type 1 (HSV1).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research